Recent Updates
Recently added Catalysts
WVE

Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference

Key Takeaway: CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Price reaction · baseline $5.68 (2021-09-21 close) · hit after-hours · clean, no other WVE news in the window
day 0 close · peak
+3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan Virtual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET.
A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Last updated: Sep 22, 2021